Absci Corporation

Absci Corporation is a clinical-stage biopharmaceutical company leveraging generative AI and synthetic biology to accelerate drug discovery and development of novel biologics. Its Integrated Drug Creation™ Platform integrates high-throughput data generation, de novo AI design, multi-parametric lead optimization, and wet-lab validation in rapid six-week cycles, enabling the creation of antibodies and therapeutics against challenging targets. The platform supports an internal pipeline, including ABS-201, an AI-designed anti-prolactin receptor antibody targeting androgenetic alopecia and endometriosis, currently in Phase 1/2a clinical trials. Absci Corporation also pursues strategic partnerships with pharmaceutical, biotech, technology, and academic organizations to advance drug creation programs like ABS-101, ABS-301, and ABS-501. Operating state-of-the-art facilities including a wet lab in Vancouver, Washington, AI research labs in New York City and Serbia, and a Drug Innovation Center in Zug, Switzerland, the company focuses on unlocking novel biology for better patient outcomes in the biotechnology sector.